Nama's AI scorecard currently rates SpyGlass Pharma Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does SGP report earnings?

SpyGlass Pharma's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.62.

What is the SGP price target?

The median analyst price target from 6 analysts is $42.00, with a range of $37.00 – $62.00.

Is SGP Shariah compliant?

Nama's AAOIFI-style screen reads SpyGlass Pharma as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

SpyGlass Pharma (SGP)

Healthcare · Biotechnology · NASDAQ

SpyGlass Pharma (SGP) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.24B and a free-cash-flow yield of -2.8%. Nama's AI scorecard rates it Sell, 2.7 out of 10.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 6, 2026.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-0.5%

How far the last close sits under the highest price of the past five years.

Market cap	$1.24B
Trailing P/E	—
Price / book	5.3
Price / sales	—
FCF yield	-2.8%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	—
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

SGP earnings

Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$0.62). Beat the EPS estimate in 0 of 2 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 6, 2026	-$0.59	-$0.55	-7.3%	$0
Q1 2026	May 14, 2026	-$0.69	-$0.36	-91.7%	$0

SGP analyst price target

Median target $42.00 from 6 analysts, ranging $37.00 – $62.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live SGP data on Nama Insights →

SGP FAQ

Is SGP a buy?: Nama's AI scorecard currently rates SpyGlass Pharma Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SGP report earnings?: SpyGlass Pharma's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$0.62.
What is the SGP price target?: The median analyst price target from 6 analysts is $42.00, with a range of $37.00 – $62.00.
Is SGP Shariah compliant?: Nama's AAOIFI-style screen reads SpyGlass Pharma as Can't Tell. A figure the screen needs is missing, so it can't tell.